Intrinsic Value of S&P & Nasdaq Contact Us
English English 中文(简) 中文(简) 中文(繁) 中文(繁) हिन्दी हिन्दी Español Español 日本語 日本語 한국어 한국어 Deutsch Deutsch Français Français
← Back to all stocks

Zealand Pharma A/S ZEAL NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • DK • USD

SharesGrow Score
56/100
2/7 Pass
SharesGrow Intrinsic Value
N/A
Negative cash flow
Analyst Price Target
$29.00
+64.9%

Zealand Pharma A/S (ZEAL) is a Biotechnology company in the Healthcare sector, currently trading at $17.59. It has a SharesGrow Score of 56/100, indicating a above average investment profile with 2 out of 7 criteria passed.

Analyst consensus target is ZEAL = $29 (+64.9% upside).

Financials: revenue is $293M, +248.8%/yr average growth. Net income is $1.0B (loss), growing at -88.9%/yr. Net profit margin is -348% (negative). Gross margin is 59.4% (+434 pp trend).

Balance sheet: total debt is $787M against $928M equity (Debt-to-Equity (D/E) ratio 0.85, moderate). Current ratio is 5.15 (strong liquidity). Debt-to-assets is 38.1%. Total assets: $2.1B.

Analyst outlook: 4 / 5 analysts rate ZEAL as buy (80%) — strong consensus.

SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 58/100 (Partial), Past 25/100 (Fail), Health 50/100 (Partial), Moat 58/100 (Partial), Future 94/100 (Pass), Income 10/100 (Fail).

$29.00
▲ 64.87% Upside
Average Price Target
Based on 5 Wall Street analysts offering 12-month price targets for Zealand Pharma A/S, the average price target is $29.00, with a high forecast of $32.00, and a low forecast of $26.00.
Highest Price Target
$32.00
Average Price Target
$29.00
Lowest Price Target
$26.00

ZEAL SharesGrow Score Overview

56/100
SharesGrow Score
Above average fundamentals
View full scorecard →
VALUE 100/100
Valuation — P/E, PEG, Forward PEG
GROWTH 58/100
Financials — average growth
PAST 25/100
strong — trend
HEALTH 50/100
Balance sheet — Debt-to-Equity (D/E) ratio, Current ratio is
MOAT 58/100
Gross margin is + market cap
FUTURE 94/100
Analyst outlook — as buy
INCOME 10/100
Net profit margin is
Scores derived from financial statements, analyst ratings, and balance sheet data.

Score Breakdown — ZEAL

✓
VALUE Pass
100/100
ZEAL trades at a trailing Price-to-Earnings (P/E) of N/A (S&P 500 average ~25). Analyst consensus target is $29, implying +64.9% from the current price $18. Composite: Price-to-Earnings (20%) + Forward Price/Earnings-to-Growth (35%) + upside (25%) + trailing PEG (20%). ≥ 60 = Pass.
View details →
~
GROWTH Partial
58/100
ZEAL: +248.8%/yr revenue is, -88.9%/yr Net income is average growth. mixed. Score: >20%/yr = 100, >10% = 80, >5% = 65, >0% = 45, < 0 = 15.
View details →
✗
PAST Fail
25/100
ZEAL: 1 / 4 years profitable. weak. Score = 1 / 4 × 100. ≥ 80 = Pass.
View details →
~
HEALTH Partial
50/100
Balance sheet ZEAL: Debt-to-Equity (D/E) ratio 0.85 (moderate), Current ratio is 5.15 (strong liquidity). Debt-to-Equity < 0.5, Current Ratio > 1.5, Interest Coverage > 8x = ideal. ≥ 70 = Pass.
View details →
~
MOAT Partial
58/100
ZEAL: Gross margin is 59.4% (+434 pp trend), N/A market cap. Moat (0-100): margin (35%) + trend (15%) + market cap (30%) + revenue is (20%). Score 58/100. ≥ 70 = Pass.
View details →
✓
FUTURE Pass
94/100
Analyst outlook: 4 / 5 analysts rate ZEAL as buy (80%). Analyst consensus target is $29 (+64.9% upside). Score: 60% buy consensus + 40% upside. ≥ 60 = Pass.
View details →
✗
INCOME Fail
10/100
ZEAL: Net profit margin is -348%. negative. Score: ≥30% = 100, ≥20% = 85, ≥15% = 70, ≥10% = 55, ≥5% = 45, ≥0% = 30, < 0 = 10.
View details →

Stock Chart & Stats

Market Data
52-Week Range9.93-32.12
Volume2.16K
Avg Volume (30D)1.76K
Beta (1Y)1.34
Share Statistics
EPS (TTM)-26.54
Shares Outstanding$38.37M
IPO Date2017-08-09
Employees237
CEOEmmanuel Dulac PharmD, MBA
Financial Highlights & Ratios
Revenue (TTM)$292.57M
Gross Profit$173.75M
EBITDA$-982.6M
Net Income$-1.02B
Operating Income$-1.02B
Total Cash$1.43B
Total Debt$787.43M
Net Debt$-341.67M
Total Assets$2.07B
Price / Earnings (P/E)-0.7
Analyst Forecast
1Y Price Target$29.00
Target High$32.00
Target Low$26.00
Upside+64.9%
Rating ConsensusBuy
Analysts Covering5
Buy 80% Hold 20% Sell 0%
Company Info
CountryDK
ExchangeNASDAQ Global Select
CurrencyUSD
ISINUS98920Y3045

Price Chart

Track all markets on TradingView
ZEAL
Zealand Pharma A/S ↗  ·  NASDAQ Global Select
Healthcare • Biotechnology
9.93 52WK RANGE 32.12

People Also View

LLY
LLY
Eli Lilly and Company
$922.50
-0.76%
 JNJ
JNJ
Johnson & Johnson
$240.10
+0.90%
 ABBV
ABBV
AbbVie Inc.
$210.32
+1.86%
 RHHBF
RHHBF
Roche Holding AG
$418.50
+1.82%
 RHHBY
RHHBY
Roche Holding AG
$51.02
+0.65%
 AZN
AZN
AstraZeneca PLC
$204.38
+1.06%
 NVSEF
NVSEF
Novartis AG
$156.48
+0.00%
 MRK
MRK
Merck & Co., Inc.
$119.96
-0.16%
Contact Us
🎓
SharesGrow Academy
Learn how to calculate Intrinsic Value and find undervalued stocks.
Weekly live sessions
📧 [email protected]
📞 +65 8912 8000
Send us a message